Puzo Michael J Has $2.10 Million Stake in Eli Lilly and Company (NYSE:LLY)

Puzo Michael J raised its position in Eli Lilly and Company (NYSE:LLY) by 288.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 2,542 shares of the company’s stock after purchasing an additional 1,887 shares during the period. Puzo Michael J’s holdings in Eli Lilly and Company were worth $2,099,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Capital & Planning LLC increased its position in shares of Eli Lilly and Company by 15.6% during the 4th quarter. Capital & Planning LLC now owns 481 shares of the company’s stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. Garner Asset Management Corp grew its position in Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock valued at $411,000 after buying an additional 12 shares during the period. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Union Bancaire Privee UBP SA bought a new stake in Eli Lilly and Company in the fourth quarter worth about $49,534,000. Finally, Revolve Wealth Partners LLC boosted its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.0%

Shares of Eli Lilly and Company stock opened at $791.61 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm has a market cap of $750.24 billion, a PE ratio of 64.41, a PEG ratio of 1.18 and a beta of 0.40. The company has a 50 day simple moving average of $777.90 and a two-hundred day simple moving average of $801.70.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the firm posted $2.58 earnings per share. The business’s revenue was up 45.2% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $1.50 dividend. The ex-dividend date was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HSBC lowered shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.